On this page, you will learn:
- What it is: NUVAXOVID is a recombinant, protein-based vaccine1
- What it’s for: NUVAXOVID is used for the prevention of COVID-19 illness and hospitalization1,2
- Who it may be for: NUVAXOVID is approved for use in people who are 65 years of age and older, or 12 years through 64 years of age with at least one underlying condition that puts them at high risk for severe outcomes from COVID-191
- How it’s used: NUVAXOVID is given as an intramuscular injection either as a primary series dose or as a seasonal dose1
NUVAXOVID is a vaccine indicated for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). NUVAXOVID is approved for use in individuals who are:
- 65 years of age and older, or
- 12 years through 64 years of age with at least one underlying condition that puts them at high risk for severe outcomes from COVID‑19.
Are your patients concerned about COVID-19 vaccine side effects?
Concerns about COVID‑19 vaccine side effects may be stopping some patients from getting protected. A 2024 survey of 1,160 US adults found that nearly half had no plans to get an updated COVID-19 booster, with 56% of that group citing side effect concerns.2
.png)
Help them do their thing with NUVAXOVID: powerful protection against COVID-19, with minimal side effect disruption to daily activities1,3
- ~90% effective against COVID-19 illness in the pivotal trial1,4*
- 100% protection against moderate-to-severe disease in the pivotal trial1,4†
- Low reactogenicity: in clinical trials, the majority of patients reported no disruption to daily activities1
- In clinical trials, the majority of side effects were mild to moderate and would not prevent daily activities, according to FDA grading1,5,6
- NUVAXOVID is the only recombinant, protein-based, non‑mRNA COVID‑19 vaccine recommended by ACIP1,3
*Primary endpoint of efficacy against symptomatic mild, moderate, or severe lab–confirmed COVID-19 occurring at least 7 days after the second dose (95% CI: 82.5, 93.8; P<0.001).1,4
†Secondary endpoint of efficacy in preventing moderate-to-severe disease from then-circulating strains of virus. NUVAXOVID may not protect all vaccine recipients (95% CI: 87.0, 100.0).1,4
See how NUVAXOVID can help provide protection with minimal disruption to daily activities.1
INDICATION
References
1. NUVAXOVID. Prescribing Information. Novavax, Inc; 2025. 2. National Foundation for Infectious Diseases. 2024 National Survey: attitudes and behaviors about influenza, COVID-19, respiratory syncytial virus, and pneumococcal disease. September 2024. Accessed January 28, 2025. https://www.nfid.org/resource/2024-national-survey-attitudes-and-behaviors-about-influenza-covid-19-respiratory-syncytial-virus-and-pneumococcal-disease/ 3. Panagiotakopoulos L, Moulia DL, Godfrey M, et al. Use of COVID-19 vaccines for persons aged ≥6 months: recommendations of the Advisory Committee on Immunization Practices—United States, 2024-2025. MMWR Morb Mortal Wkly Rep. 2024 Sep 19;73(37):819-824. doi:10.15585/mmwr.mm7337e2 4. Dunkle LM, Kotloff KL, Gay CL, et al; 2019nCoV-301 Study Group. Efficacy and safety of NVX-CoV2373 in adults in the United States and Mexico. N Engl J Med. 2022;386(6):531-543. doi:10.1056/NEJMoa2116185 5. Sanofi. Data on file 6. Food and Drug Administration. Toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventative vaccine clinical trials. September 2007.
